Ozempic and GLP-1 Blindness Lawsuit Update, Were You Affected? In re: GLP-1 RAs NAION Products Liability Litigation, MDL No. 3163

[UPDATED September 24, 2026 — Case count updated to 216 pending cases (JPML, September 1, 2026). Regulator actions, U.S. label check, court schedule and timeline rewritten. Corrected: the October 2026 discovery date is a defense proposal, not a court deadline. Settlement status unchanged: none.]

Novo Nordisk is a defendant in In re: GLP-1 RAs NAION Products Liability Litigation, MDL No. 3163, where 216 pending cases say Ozempic and similar drugs caused sudden vision loss. If that happened to you, you’re probably wondering whether there’s a lawsuit against Novo Nordisk you can join. There is one. But there’s no settlement and no claim form yet.

This isn’t a class action. Each person files an individual injury case, and the federal cases sit in one court so a single judge can rule on the questions they all share.

Novo Nordisk Ozempic Vision Loss Lawsuit — Key Facts

Detail	Information
Lawsuit Filed	Suits pending since 2024; federal cases centralized December 15, 2025
Defendant	Novo Nordisk A/S and Novo Nordisk Inc. (Ozempic, Wegovy, Rybelsus, Saxenda); Eli Lilly and Company (Trulicity, Mounjaro, Zepbound)
Alleged Harm	NAION, described by the court as sudden, permanent vision loss
Law Alleged	State product liability law: failure to warn, design defect, breach of warranties
Who Is Affected	People diagnosed with NAION after using a GLP-1 drug (individual injury claims)
Court & Case Number	E.D. Pa., Judge Karen S. Marston; MDL No. 3163, No. 2:25-md-03163-KSM
Current Stage	Early discovery on general causation and preemption; 216 pending cases (JPML, Sept. 1, 2026)
Lead Plaintiff Deadline	N/A. Not a class action
Settlement Status	None. No claim form, no administrator
Last Updated	September 24, 2026

Who Is Novo Nordisk and Why Are They Being Sued for Ozempic Vision Loss?

Novo Nordisk makes Ozempic, Wegovy and the semaglutide pill, and it controls what the U.S. labels tell doctors about eye risks. Plaintiffs say those labels never warned about NAION, and the Ozempic label revised in May 2026 still doesn’t mention it. Honestly, this is mostly a Novo Nordisk case, since only 19 of the 137 cases counted in June name Eli Lilly.

What Did Novo Nordisk Allegedly Do to Ozempic Patients Between 2017 and 2026?

Plaintiffs’ core claim is simple. They say Novo Nordisk sold Ozempic without warning patients or doctors that it could cause NAION, which the court describes as a condition that results in sudden, permanent vision loss. The Judicial Panel’s transfer order lists three claims, failure to warn, design defect and breach of warranties, all rooted in state product liability law, which lets an injured person sue a drugmaker over a product that lacked a needed safety warning.

The science starts with a July 2024 JAMA Ophthalmology study that reported a hazard ratio of 7.64 for overweight or obese patients taking semaglutide. That sounds huge until you see the confidence interval, 2.21 to 26.36, and learn the authors said a single-center observational study can’t prove cause. Regulators later landed lower.

Some plaintiffs allege both eye and stomach injuries, which is why our earlier explainer, GLP-1 Lawsuit, Stomach Paralysis, Blindness Claims, And What 2,914 Victims Need To Know About Ozempic Legal Case, is worth a read if that’s you. Either way, the eye claim will be tested on the gap between 7.64 and roughly double, and the court has already ordered that testing to go first.

What Do Regulators and the U.S. Label Say About Novo Nordisk’s Ozempic and NAION?

Europe moved first. In June 2025, the EMA’s safety committee concluded that NAION is a very rare semaglutide side effect that may affect up to 1 in 10,000 people, and it recommended a label update. The WHO issued its own alert later that month, the UK’s MHRA followed with a Drug Safety Update on February 5, 2026, and Australia’s TGA updated warnings across the whole GLP-1 class on July 23, 2026.

Here’s a detail that gets lost. The EMA put the added risk for adults with type 2 diabetes at roughly double, or about one extra case per 10,000 person-years of treatment, and Australia’s advisory committee found evidence that may support the signal for semaglutide but not for Trulicity or tirzepatide. That split matters because the federal case also covers Lilly’s Trulicity, Mounjaro and Zepbound.

Even the wording is careful. The TGA’s new semaglutide warning says “Some epidemiological studies indicate an increased risk of NAION during treatment with semaglutide,” and adds that people with an anatomical predisposition face the highest risk whether or not they take a GLP-1 drug.

Now the U.S. side. The FDA-hosted Ozempic label, revised in May 2026, doesn’t list NAION in its warnings or its postmarketing section. Its only eye-related warning is Section 5.3 on diabetic retinopathy complications, plus a Medication Guide line telling patients to report changes in vision.

Whether that vision language counts as an adequate warning is the question Judge Marston has put on the fast track. For the wider FDA warning history on these drugs, see Weight Loss Drug Lawsuits 2026, FDA Warnings And New Vision Loss And GI Injury Claims January 2026 Update. Honestly, a lot of this litigation comes down to what that one page says.

Where Does the Novo Nordisk Ozempic Vision Loss Lawsuit Stand Right Now?

Start with the count. The JPML’s monthly reports put the vision loss MDL at 146 pending cases on July 1, 200 on August 3 and 216 on September 1, 2026. That’s 54 new cases in the first stretch and 16 in the second.

The stomach-injury docket, MDL 3094, added 80 and then 94 over the same reports and now sits at 4,022. At 216, the eye docket is about 5% of that size.

Honestly, the drop from 54 new cases to 16 jumped out at me when I lined the reports up. One month isn’t a trend. But it’s worth watching, because filing pace is one of the few public signals of how many people are joining.

On July 2, 2026, Judge Marston issued Case Management Order No. 12. She granted the defendants’ request to decide two questions first: whether GLP-1 drugs can cause NAION in the general population, and whether federal law blocks the warning claims or the label already covers them. Plaintiffs had asked for a “pilot case” approach instead, and she declined to consider the bellwether selection they raised at the hearing because their briefs hadn’t requested it.

Defendants proposed finishing fact discovery in October 2026, expert discovery by year-end and motions fully briefed in early 2027. The judge called that somewhat optimistic and suggested briefing might run to mid-2027. She ordered the sides to propose a schedule, and the court’s posted orders still stop at Order No. 12.

So the October date is a proposal.

Judge Marston holds status conferences in Courtroom 16B. The next is October 13, 2026 at 11:00 a.m., followed by November 17 and December 15, and her April 30 order shows none for August or September.

New Jersey runs a parallel case. The state Supreme Court created a separate NAION multicounty litigation before Judge Gregg A. Padovano in Bergen County, and the federal judge noted on July 2 that the related state cases were still at the pleadings stage with no scheduling orders.

No trial date appears in the court’s posted orders, and even the defendants’ fast schedule doesn’t finish briefing the first big motions until early 2027.

Are You Part of the Novo Nordisk Ozempic Vision Loss Lawsuit?

Here’s exactly how to know if you’re part of the Ozempic lawsuit. It’s a defective product lawsuit against the drugmakers, so your doctor isn’t a defendant.

• People prescribed Ozempic, Wegovy, Rybelsus, Saxenda, Trulicity, Mounjaro or Zepbound for type 2 diabetes or long-term weight management
• Patients who were later diagnosed with NAION
• Anyone who can show both, since the court has told the sides to plan for records proving use and diagnosis
• Those who also have stomach injuries, because some plaintiffs allege both

Who doesn’t fit: people with stomach-only injuries belong in MDL 3094, covered in Ozempic Lawsuit April 2026 Latest Updates 3,546 Cases, FDA Warning & Science Day Scheduled. Anyone without a NAION diagnosis is outside this docket’s injury. And expect a hard look if you have known NAION risk factors, which the EMA lists as diabetes, high blood pressure, high cholesterol and severe overweight.

Did you lose vision in one eye after starting one of these drugs? Then this case is asking about you.

Novo Nordisk Ozempic Users Outside Pennsylvania — Are You Still Covered?

Yes. The federal cases came in from New Jersey, Pennsylvania and Texas courts, and the Direct Filing Order (CMO No. 4, January 29, 2026) sets up filing straight into the MDL. Product liability rules come from state law, so your state’s filing deadline is the one that matters. It’s a personal injury case, not a class, so no single nationwide deadline exists.

Not sure if you qualify for the Novo Nordisk Ozempic vision loss lawsuit? A free legal consultation with a product liability attorney can help before your state’s filing deadline runs out.

What Are Novo Nordisk Ozempic Vision Loss Plaintiffs Asking the Court to Award?

Plaintiffs want compensation for damages: medical bills, lost income and pain and suffering, and some seek punitive damages. No court has set a dollar figure. No money yet. No claim form yet.

Not one case has been tried, and no verdict or settlement exists.

What Could Novo Nordisk Ozempic Users Receive If This Settles?

Nobody can predict it. It would depend on how many people file, the evidence in each case and negotiations, and any payout would vary by person. You’ll see ranges like $400,000 to $700,000 on law firm sites, but those are marketing estimates, not court findings. A product liability attorney can explain what your own case might involve.

What Should Novo Nordisk Ozempic Vision Loss Patients Do Right Now?

1. Know that nobody is automatically included. Unlike a class action, you join by filing your own case.
2. Save your records today. Keep pharmacy and prescription history, drug packaging, eye exam notes, imaging and a dated timeline of when you started the drug and lost vision.
3. Protect your health first. Regulators say sudden vision loss needs urgent medical care. Don’t stop a prescription without talking to your doctor, and consider reporting the event to FDA MedWatch.
4. Skip the lead plaintiff deadline. It doesn’t exist here. The clock that matters is your state’s statute of limitations, and some are short.
5. Watch the docket. The Eastern District of Pennsylvania posts every order on its MDL page, and the public can watch the monthly status conferences remotely.
6. Talk to a lawyer. Many mass tort firms work on contingency, which means fees come out of any recovery. Ask about that up front.

Novo Nordisk Ozempic Vision Loss Lawsuit — Full Timeline

Milestone	Date
Ozempic receives initial FDA approval	2017
Earliest suits in the JPML order pending (e.g., Kane v. Novo Nordisk A/S, No. 3:24-cv-11384)	2024 (per docket numbers)
JAMA Ophthalmology study on semaglutide and NAION	July 2024
EMA safety committee concludes NAION is a “very rare” side effect	June 6, 2025
WHO alert on semaglutide and NAION	June 27, 2025
N.J. Supreme Court orders create separate NAION multicounty litigation	October 16, 2025 (notice published November 12, 2025)
JPML creates the NAION MDL (21 actions, three districts)	December 15, 2025
Direct Filing Order (CMO No. 4)	January 29, 2026
MHRA Drug Safety Update	February 5, 2026
Plaintiffs’ leadership counsel appointed (CMO No. 5)	February 23, 2026
Science Day ordered for June 2, 2026 (CMO No. 6)	March 16, 2026
Status conference on early discovery	June 23, 2026
Pending cases	146 (July 1, 2026)
CMO No. 12 grants early discovery on causation and preemption	July 2, 2026
Proposals due on schedule and plaintiff fact sheets	July 13, 2026
TGA class-wide product warning update	July 23, 2026
Pending cases	200 (August 3, 2026)
Pending cases	216 (September 1, 2026)
Defendants’ proposed close of fact discovery	October 2026 (proposal only)
Next status conference	October 13, 2026
Expected resolution	UNVERIFIED — no settlement or trial date exists

Novo Nordisk Ozempic Vision Loss — Frequently Asked Questions, MDL No. 3163

Is there a class action lawsuit against Novo Nordisk for Ozempic vision loss right now?

No. The federal cases are individual injury lawsuits grouped before one judge in the Eastern District of Pennsylvania. The JPML counted 216 pending cases on September 1, 2026. New Jersey runs a parallel state proceeding in Bergen County.

Do I need to do anything right now to be part of the Novo Nordisk Ozempic lawsuit?

Yes, because nobody is automatically included. You join by filing your own case, usually through a product liability attorney. Save pharmacy and eye exam records now, since the court told both sides to plan for fact sheets covering proof of use and proof of diagnosis.

When will the Novo Nordisk Ozempic vision loss case settle?

Nobody can say. No settlement exists and no trial date has been set. Defendants proposed finishing fact discovery in October 2026, but Judge Marston called that somewhat optimistic and suggested briefing might run to mid-2027. Early rulings on causation and preemption come first.

Can I file my own lawsuit against Novo Nordisk instead of joining a class?

Yes. Every case here is already an individual injury lawsuit. The Direct Filing Order (CMO No. 4, January 29, 2026) lets new cases go straight into the federal MDL, while cases filed in New Jersey state court go to Bergen County. An attorney can tell you which fits.

How will I find out if the Novo Nordisk Ozempic lawsuit settles?

If you’ve filed, your attorney will tell you. Everyone else can watch the Eastern District of Pennsylvania’s MDL page, which posts every case management order. Status conferences run October 13, November 17 and December 15, 2026. No settlement website or administrator exists yet.

What does “lead plaintiff” mean for the Novo Nordisk case, and why doesn’t a deadline apply?

A lead plaintiff deadline applies to class actions, where one person represents everyone. This isn’t one. Instead, the court appointed plaintiffs’ leadership counsel on February 23, 2026 (CMO No. 5) to run discovery for all plaintiffs. Your deadline is your state’s statute of limitations.

What specific laws does Novo Nordisk allegedly violate?

The Judicial Panel’s transfer order lists failure to warn, design defect and breach of warranties. Those come from state product liability law, not one federal statute, so your state’s rules apply. Individual complaints can add other claims. Novo Nordisk hasn’t been found liable under any of them.

How much could Novo Nordisk Ozempic users get if this case settles?

No court has set a number. Figures like $400,000 to $700,000 on law firm sites are marketing estimates, not findings. Any compensation for damages would depend on your diagnosis, medical costs, lost income and state law. No settlement fund exists.

Sources Used in This Novo Nordisk Ozempic Vision Loss Article

• JPML — Transfer Order, MDL No. 3163, Doc. 49, December 15, 2025: https://www.jpml.uscourts.gov/sites/jpml/files/MDL-3163-Transfer_Order-12-25.pdf
• JPML — Pending MDL Dockets by Actions Pending, July 1, 2026: https://www.jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_Actions_Pending-July-1-2026.pdf
• JPML — Pending MDL Dockets by Actions Pending, August 3, 2026: https://www.jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_Actions_Pending-August-3-2026.pdf
• JPML — Pending MDL Dockets by Actions Pending, September 1, 2026: https://www.jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_Actions_Pending-September-1-2026.pdf
• E.D. Pa. — Case Management Order No. 12, Doc. 120, July 2, 2026: https://www.paed.uscourts.gov/sites/paed/files/mdl-orders/25md3163_cm-ord_12.pdf
• E.D. Pa. — Case Management Order No. 6 (Science Day), Doc. 67, March 16, 2026: https://www.paed.uscourts.gov/sites/paed/files/mdl-orders/25md3163_cm-ord_6.pdf
• E.D. Pa. — Order on status conferences, Doc. 86, April 30, 2026: https://www.paed.uscourts.gov/sites/paed/files/mdl-orders/25md3163_sched-ord_2.pdf
• E.D. Pa. — MDL orders list, checked September 24, 2026: https://www.paed.uscourts.gov/mdl/mdl3163/orders
• N.J. Courts — Notice to the Bar on GLP-1 multicounty litigation, November 12, 2025: https://www.njcourts.gov/notices/notice-and-orders-multicounty-litigation-designation-of-litigation-involving-glp-1-products
• FDA — Ozempic prescribing information, revised 05/2026: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/209637s038lbl.pdf
• EMA — PRAC conclusion on NAION and semaglutide, June 6, 2025: https://www.ema.europa.eu/en/news/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempic-rybelsus-wegovy
• MHRA — Drug Safety Update, February 5, 2026: https://assets.publishing.service.gov.uk/media/69847cb7468d351e1406b4d2/DSU_-Semaglutide_and_NAION-_5_Feb_2026.pdf
• TGA — GLP-1 RAs and rare vision disorder, July 23, 2026: https://www.tga.gov.au/news/safety-updates/glp-1-ras-and-rare-vision-disorder
• WHO — Semaglutide medicines and NAION, June 27, 2025: https://www.who.int/news/item/27-06-2025-27-06-2025-semaglutide-medicines-naion
• PubMed — Hathaway et al., JAMA Ophthalmology, 2024: https://pubmed.ncbi.nlm.nih.gov/38958939/

Researched and written by Israr Ahmad, legal content researcher and founder of AllAboutLawyer.com. All facts verified against the E.D. Pa. court orders, the JPML monthly reports, the FDA-hosted Ozempic label and regulator notices on September 24, 2026. Last Updated: September 24, 2026.

This article is for informational purposes only and does not constitute legal advice. Laws vary by state and individual circumstances differ. For advice about your specific situation, consult a qualified attorney.